Genetically engineered T cells expressing a chimeric antigen receptor (CAR) are rapidly emerging as a promising new treatment for haematological and non-haematological malignancies. CAR-T therapy can induce rapid and durable clinical responses but is associated with unique acute toxicities. Moreover, CAR-T cells are vulnerable to immunosuppressive mechanisms. Here, we report that CAR-T cells release extracellular vesicles, mostly in the form of exosomes that carry CAR on their surface. The CAR-containing exosomes express a high level of cytotoxic molecules and inhibit tumour growth. Compared with CAR-T cells, CAR exosomes do not express Programmed cell Death protein 1 (PD1), and their antitumour effect cannot be weakened by recombinant PD-L1 treatment. In a preclinical in vivo model of cytokine release syndrome, the administration of CAR exosomes is relatively safe compared with CAR-T therapy. This study supports the use of exosomes as biomimetic nanovesicles that may be useful in future therapeutic approaches against tumours.
The utilization of genetically engineered autologous or allogeneic T cells expressing chimeric antigen receptors (CARs) or T-cell receptors (TCRs) as cellular immunotherapy is emerging as a promising new treatment method for a broad range of cancers, based on the cytotoxic specificity of the T cells towards cancer cells. Typically, CARs consist of a target binding domain, which is an extracellular domain that is specifically expressed by CAR-T cells, a transmembrane domain, and a signalling domain, which is an intracellular domain that provides an activation signal to T cells. The targeting specificity of CARs is usually achieved by antigen-recognition regions in the form of a single-chain variable fragment (scFv) or a binding receptor/ligand in the extracellular domains, while the T-cell-activating function is achieved by the intracellular domain, including a region of the TCR CD3 chain that provides ‘signal 1’ and one or more domains from co-stimulatory receptors, such as CD28, OX40 (CD134), and/or 4-1BB (CD137), to provide ‘signal 2’. In current clinical development, targeting CD19+ B-cell malignancies, which include acute and chronic B-cell leukaemia and B-cell non-Hodgkin lymphomas (B-NHLs), with anti-CD19 CAR-T cells is one of the most advanced adoptive T-cell therapies and has been approved by the FDA. Data from numerous phase I/II clinical trials conducted at single institutions have indicated that this approach is typically associated with an overall response rate of 50–90% in patients with B-cell malignancies refractory to standard therapies.

Despite their efficiency, adoptive T-cell therapies show unique toxicities, which are distinct from those seen with conventional chemotherapies, monoclonal antibodies (mAbs), and small-molecule-targeted therapies. The recognition of toxicity is of utmost importance as the use of these therapies increases. The two most commonly noticed toxic effects in CAR-T immunotherapy are cytokine release syndrome (CRS), which is characterized by high fever, hypotension, hypoxia, and/or multiorgan toxicity, and CAR-T-related encephalopathy syndrome (CRES), which is typically characterized by a toxic encephalopathic state with symptoms of delirium, confusion and, occasionally, cerebral oedema and seizures. Rare cases of fulminant haemophagocytic lymphohistiocytosis (HLH) (or macrophage-activation syndrome (MAS)), typically characterized by severe immune activation, lymphohistiocytic tissue infiltration, and immunemediated multiorgan failure, have also been reported.

Other redirected T-cell therapies, such as TCR gene therapies and bispecific T-cell-engaging antibodies (BiTEs), as well as preclinical CAR natural killer (NK) cells, have also been reported to induce such toxicity. Although a strong response was observed for CAR-T cells in patients with treatment-refractory haematologic malignancies, only modest outcomes have been reported in solid tumours. This result is probably due to a host of obstacles that are encountered in the tumour microenvironment (TME) of solid tumours, including intrinsic inhibitory pathways mediated by upregulated inhibitory receptors (IRs) responding to their cognate ligands within the tumour, such as in PD1 signalling.

Exosomes belong to a sub-group of extracellular vesicles (EVs), which are secreted by most cells in the body. EVs can be divided into three sub-groups based on their biogenesis, including exosomes (30–150 nm in diameter), microvesicles (150–1000 nm) and apoptotic bodies (50–2000 nm). Recently, cumulative evidence has emerged, suggesting that membrane vesicles may play a crucial role as mediators of intercellular communication. Exosomes have received the most attention among these vesicles and have also been substantially characterized. Moreover, regarding human T-cell-derived exosomes, their essential role in cytotoxic T lymphocyte (CTL)-target cell interactions was verified in previous studies. CTL-derived exosomes contain CTL surface membrane molecules (CD3, CD8 and the TCRs), guaranteeing the unidirectional delivery of the lethal hit to targeted tumour cells.

Results
Characterization of CAR exosomes. Chimeric receptors are designed to contain scFv derived from antibodies that recognize human EGFR and HER2. Cetuximab and trastuzumab were chosen because these antibodies have been found to be safe in patients when administered as targeted drugs. The second-generation CAR design, which includes scFv fused to a CD8a hinge and transmembrane domain and the intracellular domains of human 4-1BB and CD3ζ (or z), was used in our study (Fig. 1a).

Next, we used lentiviral vector technology to express the fusion constructs in primary human T cells using clinically validated techniques. The cDNA sequences containing the various fusion constructs were cloned into a third-generation lentiviral vector in which the CMV promoter was replaced with the EF-1α promoter. The receptors were cloned using an extracellular MYC epitope and a C-terminal FLAG tag to permit detection by immunoblotting and flow cytometry. Lentiviral vector supernatants transduced primary T cells with high efficiency (Fig. 1b and Supplementary Fig. 1).

Next, we investigated the antitumour potential of the transduced T cells by standard 51Cr-release assays using MCF-7 cells (EGFR- and HER2-negative cells), MCF-7 EGFR cells (a derivative engineered to express EGFR), MCF-7 HER2 cells (a derivative engineered to express HER2), MDA-MB-231 cells, HCC827 cells, and SK-BR-3 cells. The EGFR and HER2 expression levels of these cell lines were measured, and the results are shown in Supplementary Table 1. CAR-T cells transduced with cetuximab scFv (termed CAR-T-CTX) efficiently lysed EGFR-positive cells, such as MCF-7 EGFR cells, MDA-MB-231 cells, and HCC827 cells, as well as SK-BR-3 cells, but did not kill MCF-7 cells. On the other hand, CAR-T cells transduced with trastuzumab scFv (termed CAR-T-CTT) efficiently lysed HER2-positive cells, such as MCF-7 HER2 cells, HCC827 cells and SK-BR-3 cells, but not MCF-7 cells or MDA-MB-231 cells (Fig. 1c, d).
We stimulated CAR-T-CTX or CAR-T-TTZ cells with a previously described two-stage strategy over the course of 2 weeks in vitro\(^\text{34}\), isolated T cells were first stimulated with anti-CD3/CD28-coated beads. The timing of the second stimulation was based on the return to the resting cell size because cell size is a marker of the lymphocyte activation state, and restimulation of resting lymphocytes reduces activation-induced cell death\(^\text{29}\). Irradiated antigen-expressing cells (MDA-MB-231 cells or SK-BR-3 cells) or anti-CD3/CD28-coated beads were used for the second-stage stimulation, and exosomes were harvested from the culture supernatant using well-established ultracentrifugation protocols\(^\text{30}\). Analysis by enzyme-linked immunosorbent assay (ELISA) and western blotting revealed the presence of CAR expression in exosomes, and its level was significantly higher in exosomes derived from antigen-stimulated CAR-T cells than in those from anti-CD3/CD28 bead-stimulated (Fig. 2a–d). Using different antigen stimulation strategies, such as antigen-expressing COS cells or recombinant antigen-coated beads, also produced a high level of CAR expression in exosomes (Fig. 2e). Iodixanol density gradient centrifugation further confirmed the association of CAR with exosomes (Supplementary Fig. 2a).

T-cell surface CAR can bind to antigen through its extracellular domain to achieve a targeting effect\(^\text{31}\). Using an ELISA and immunoblotting (Fig. 2a–e), we found that exosomal CAR has the same membrane topology as cell surface CAR, with its extracellular domain exposed on the surface of the exosomes. Exosomal CAR binds antigen in a concentration-dependent manner, and this interaction can be disrupted by blocking antibodies (Fig. 2f). CAR was also detected in microvesicles but at a lower level (Fig. 2g, h). Exosomes are generated and released through a defined intracellular trafficking route\(^\text{32,33}\). Genetic knockdown of the ESCRT subunit Hrs, which mediates the recognition and sorting of exosomal cargos\(^\text{34}\), using short hairpin (sh)RNA led to a decreased level of CAR expression in the exosomes (Supplementary Fig. 2b, c).

To further characterize this type of exosome, CAR-containing exosomes were purified using recombinant EGFR- or HER2-coated paramagnetic beads. We obtained 0.1–2 μg of CAR exosomes (based on the protein concentration) per 10⁶ CAR-T cells by repeated antigen stimulation. However, we could not purify sufficient CAR exosomes for the subsequent assays from CAR-T cells with repeated CD3/CD28-bead stimulation. Purified CAR exosomes were termed CAR-EXO-CTX and CAR-EXO-TTZ. CAR exosomes carry surface CAR protein at a level of 0.6 ng per μg of exosomes, as determined by ELISA, which is comparable to the expression level of CARs in CAR-T cells (Supplementary Fig. 3). The exosomes produced were physically homogeneous, with a size distribution peaking at an 80-nm diameter, as determined by nanoparticle tracking analysis (NTA) and electron microscopy (Fig. 3a–c). Further characterization of
T-cell exosomes by western blot analysis confirmed the presence of typical exosomal proteins after purification but also excluded the presence of contaminating proteins during purification from the endoplasmic reticulum, Golgi, mitochondria, and nucleus (i.e., the calregulin, Golgi 58K, prohibitin, and nucleoporin molecules, respectively), potentially derived from apoptotic or necrotic cells. These results were consistent with those obtained using flow cytometry analysis after exosome coupling to latex beads. In fact, CAR-containing exosomes expressed appreciable levels of both CAR and CD63, further confirming their exosomal nature, as well as MHC I proteins and a substantial amount of CD3, CXCR4, and CD57, whereas CD27 receptor and CD28 were expressed at relatively low levels, and CD45 RA and PD-1 receptor were undetectable.

**Cytolytic activity of CAR exosomes.** CTL and NK cells are known to exert their cytolytic activity through the release of cytotoxic effectors (i.e., granzyme B and perforin) contained in lytic granules. Upon target cell recognition and conjugation, the granules are actively directed to the site of cell–cell contact, and soluble effector molecules are released into the forming cytotoxic immunological synapse. Thus, we first evaluated the presence of granzyme B and perforin on CAR exosomes by flow cytometry analyses of exosome-bead complexes. The results showed that perforin and granzyme B molecules were notably expressed on CAR-EXO-CTX and CAR-EXO-TTZ (Fig. 4a and Supplementary Fig. 1). Further western blot analysis revealed the presence of both granzyme B and perforin in CAR-T cells and CAR exosomes (Fig. 4b).

To test the potential bioactivity of granzyme B and perforin expressed by CAR exosomes, we investigated their cytotoxic effect against human tumour cell lines and exosomes from non-transduced T cells, which served as the control (Fig. 4c). In a panel of cell lines, CAR-EXO-CTX and CAR-EXO-TTZ show notable cytotoxic effects on EGFR-expressing cells or HER2-expressing cells, while cancer cells with low antigen expression seemed to be resistant to exosome-mediated lysis (Supplementary Table 1). These data suggested that CAR exosomes can exert strong and specific cytotoxic activity against cancer cells. Exosomes may undergo uptake by tumour cells through a fusion-mediated mechanism. Figure 4d shows that CAR-EXO-CTX, labelled with NHS-Rhodamine dye (red), was detected...
CAR exosomes have potent antitumour activity in vivo. Having demonstrated both the specificity and cytotoxicity of CAR exosomes in vitro, we sought to confirm the in vivo antitumour activity of these exosomes. To support the idea that CAR exosomes have no undesired toxicity, in our study, we conducted a 13-week repeat-dose toxicity study with a 4-week recovery period. The maximum tolerated dose (MTD) was defined as the dose at which no deaths occurred, and the body weight loss was ≤20% of the animal weight pretreatment. In this study, animals injected with CAR exosomes exhibited no signs of toxicity, even at the highest dose tested (Supplementary Fig. 4). Thus, the MTD of the CAR exosomes was not reached in this study.

CAR-EXO-CTX showed dose-dependent tumour growth inhibition (TGI) in both MDA-MB-231 and HCC827 mouse xenograft models (Fig. 5a). Intravenous doses of 100–150 μg of CAR-EXO-CTX were notably efficacious, achieving more than 70% TGI compared with the controls. Only partial TGI was observed with 25 to 50 μg of CAR-EXO-CTX, indicating suboptimal dosing. In a HER2+ cell line-based mouse xenograft model, 100–150 μg of CAR-EXO-TTZ treatment also showed a marked antitumour effect with approximately 67% TGI. To further examine the specificity, we further characterized the antitumour effect of CAR exosomes using different recombinant antigens in vivo. Our data showed that the injection of CAR-EXO-CTX notably inhibited the growth of tumours derived from MDA-MB-231 cells, whereas combined treatment of the exosomes with EGFR-Fc protein antibodies, but not with IgG isotype antibodies or HER2-Fc protein, reversed the effect (Fig. 5b). Moreover, in the SK-BR-3 xenograft model, although CAR-EXO-TTZ notably inhibited tumour growth, this effect was weakened by combining exosomes with the HER2-Fc protein (Fig. 5c).

Additionally, we observed that the antitumour efficacy of single-agent CAR exosomes induced potent TGI in EGFR- or HER2-positive human cancer cell line models or patient-derived xenograft models (Fig. 5d and Supplementary Fig. 5). Treatment with 4–5 cycles of weekly exosome treatment at doses of 100 μg resulted in TGI in all five EGFR-positive NSCLC models and four PDX models. Substantial TGI (>50%) was also observed in three HER2+ cancer cell line xenograft models and two PDX models after CAR-EXO-TTZ treatment.

CAR exosomes do not express PD-1. Because human CAR-T cells may be reversibly inactivated within the solid tumour microenvironment of some tumours via multiple mechanisms, such as the PD-1 pathway, we next sought to investigate whether CAR exosomes may be inactivated for the same reason. The current model for PD-L1-mediated immunosuppression is based on the interaction between PD-L1 on the tumour cell surface and PD-1 on T cells. Recombinant PD-L1 protein treatment resulted in decreased proliferation and decreased IFN-γ, IL-10, IL-4, and IL-2 secretion from anti-CD3-stimulated T cells in vitro37,38. Moreover, recombinant PD-L1 was reported to promote in vivo cardiac allograft survival and protection from chronic rejection39, long-term pancreas islet allograft survival40, and protection of mouse survival in models of colitis41. Therefore, we first tested whether PD-L1 inhibits CAR-T cells. Recombinant PD-L1 treatment notably inhibited the proliferation, cytokine production and cytotoxicity of CAR-T cells, as demonstrated by the reduced expression of Ki-67 and granzyme B (GzmB) in CAR-T cells and the inhibited production of IFN-γ, IL-2, and TNF (Fig. 6a–c and Supplementary Fig. 1). Combined treatment with
the recombinant PD-L1 and anti-PD-L1 antibodies nearly abolished these effects. Moreover, pre-treating CAR-T cells with recombinant PD-L1 inhibited their ability to kill their target cells (Fig. 6d e). Conversely, adding recombinant PD-L1 to CAR exosomes did not cause significant loss of cytolytic activity in cell line assays; the cause may be the leak of PD-1 expression of CAR exosomes. We next examined the effects of PD-L1 on CAR-T cells or CAR exosomes in vivo, and injection of CAR exosomes notably inhibited the growth of tumours derived from MDA-MB-231 cells or SK-BR-3 cells, with or without combined PD-L1 treatment, whereas combined treatment of the CAR-T cells with the PD-L1 protein, but not with IgG isotype antibodies, inhibited the antitumour effect (Fig. 6f). Similar results were also observed when CAR exosomes or CAR-T cells were administered via the intratumoural (i.t.) route (Supplementary Fig. 6). These data suggest that PD-L1 suppresses the antitumour immunity of CAR-T cells but not exosomes.

No observation of CRS after CAR exosome immunotherapy. A previous report showed that T cells engineered with a broad-ErbB dimer targeting CAR, T1E28z, recognize both human and mouse ErbB+ cells and show dose-dependent side effects similar to CRS in mice when delivered intra-peritoneally (i.p.)42,43. We next sought to determine whether exosomes may ameliorate CRS risk in similar models. We fused a T1E sequence with a CD8a hinge and transmembrane domain and the intracellular domains of human 4-1BB and CD3ε similar to CAR-T-CTX and CAR-T-TTZ, and this construct was termed CAR-T-T1E (Supplementary Figs. 1 and 7). Consistent with a previous report42, co-cultivation experiments demonstrated that CAR-T-T1E cell recognition of cancer cells expressed all possible EGFR- or HER3-based dimers, leading to the production of IL-2, TNF and IFN-γ, whereas CAR-T-CTX and CAR-T-TTZ were only activated by the corresponding antigen-expressing cells (Supplementary Fig. 8). Moreover, CAR-T-T1E efficiently lysed MDA-MB-231 cells and HCC827 cells but exerted a weaker effect on SK-BR-3 cells and MDA-MB-435 cells (Fig. 7a). CAR-T-T1E also exerted a striking antitumour effect on MDA-MB-231 cell-based xenografts (Fig. 7b). Next, CAR-T1E exosomes were detected by ELISA and purified using methods similar to those used in our previous experiments, and they were termed CAR-EXO-T1E (Fig. 7c). As expected, CAR-EXO-T1E also show cytolytic activity in MDA-MB-231 cell monolayers and antitumour effects on MDA-MB-231 xenografts (Fig. 7d e).

It was reported that T1E-CAR-containing T cells can cause dose-dependent toxicity similar to CRS when delivered i.p. in SCID beige mice43. To confirm this result in our experiments, groups of mice were treated with escalating doses of CAR-T-T1E immunotherapy, administered i.p. Because there was a risk of severe toxicity induction, only three mice were included in each group for ethical reasons. Animals that received 5 or 15 million cells exhibited no alteration in behaviour or weight during the ensuing 48 h. In contrast, animals that received 45 million cells demonstrated subdued behaviour, piloerection, and reduced mobility within 24 h, accompanied by rapid weight loss (Fig. 7f),
and all animals died within 48 h. Serial blood samples revealed that human IFN-γ, human IL-2, and mouse IL-6 (Fig. 7g) were all detectable in the circulation of mice that had received a lethal dose of CAR-T cells. Next, we examined whether CAR-EXO-T1E has a similar risk of cytokine release in response to immunotherapy. Different doses of CAR-EXO-T1E were administered by i.p. in mice. In all groups of mice, no alteration in behaviour or weight gain was observed, and human cytokines were not detected in the circulation of these mice (Fig. 7h, i).

**Discussion**

CAR-based adoptive immunotherapies, which use genetically modified T lymphocytes to provide both tumour targeting and immune responses, can act as living drugs that exert constant cytotoxic attacks on targeted cells. The tumour-killing capacity of CAR-T cells relies on the life span of the cells themselves and on further in vivo replication. However, CAR-T cells and the replication of these cells in vivo can boost cytokine release, which is not suitably controllable. This effect is a potential source of adverse effects, such as CRS, the cytokine storm and on-target, off-tumour responses. In solid tumours, CAR-T therapy has not achieved the clinical success that has been observed in haematological malignancies. One reason for the poor treatment response is the failure of CAR-T cells to accumulate and replicate in hostile tumour microenvironments. Moreover, CAR-T-cell inactivation and possible exclusion from the tumour mass, reciprocal interactions between stromal cells and tumours, and the propensity of cancers such as prostate cancer to disseminate preferentially to bones may all be due to the absence of a substantial CAR-mediated T-cell response in solid tumours.

In this report, we show that CAR exosomes, which are released from CAR-T cells, also hold great therapeutic potential for attacking cancer cells. Using exosomes as direct attackers for cancer therapy may have several obvious advantages. CAR exosomes may have a low risk of toxicities, such as CRS, and CAR exosomes can be generated from healthy donors and therefore have the potential to be an ‘off-the-shelf therapeutic’. The manufacturing process of the cell-free vesicles is also safer than that of living CAR-T cells, supported by a recent case report showing that the CAR gene was unintentionally introduced into a single leukaemic B cell during T-cell manufacturing and that its product masking it from recognition by and conferring resistance to CTL019; the patient ultimately died of complications related to progressive leukaemia. Second, because exosomes have a nanoscale size, they have the advantage of being utilized for solid tumour therapy. The appropriate use of exosomes paves the way
to targeting tumour cells in specific regions, such as glioblastomas. Third, the combined and/or alternate utilization of these two platforms (i.e., CAR-T cells and CAR exosomes) will undoubtedly strengthen the use of CAR-based cancer therapy; our data show that eventually, PD-L1 treatment did not impede exosome cytotoxicity, suggesting that CAR exosome treatment can overcome immunosuppressive mechanisms. For the clinical application of CAR exosomes, the proposed scheme includes T-cell isolation from the peripheral blood of healthy donors or cancer patients, genetic engineering of T cells to express CARs, in vitro replication and stimulation of CAR-engineered T cells, isolation of exosomes, purification of CAR exosomes, and exosome infusion into patients. All the reported and standard approaches can be used to isolate exosomes from culture media, including ultrafiltration, ultracentrifugation and affinity capture on magnetic beads. CAR exosomes can be further purified by antigen-coated magnetic beads as used in our study.

Because of the different natural properties between CAR-T cells and CAR exosomes, we cannot simply compare the kill efficiency. Our data show that 5 × 10⁴ CAR-T cells or 10 μg CAR exosomes can cause approximately 20% killing of 5000 tumour cells. However, unlike cell-based treatment, the exact number of exosomes present in 1 μg of protein is controversial based on current methods. We used ELISA to quantify CAR expression in CAR-T cells and CAR exosomes. There are approximately 0.25 –0.69 ng CAR protein per μg CAR-T cells based on the protein concentration, corresponding to approximately 10 ng CAR protein per 5 × 10⁴ CAR-T cells, while there are approximately 0.6 ng CAR protein per 1 μg CAR exosomes (6 ng per 10 μg CAR exosomes). The CAR protein level is very comparable between CAR-T cells and CAR exosomes used to achieve similar cell lysis effects in vitro. The present study has limitations. We provide evidence that the targeting effect and antitumour effect with CAR exosomes can be achieved, but whether CAR signalling or the granzymes are required for the action mode is unknown. Moreover, the precise mechanisms responsible for these therapeutic effects are currently not well characterized. Hence, these findings will need further validation.

To conclude, engineered T-cell adoptive immunotherapy is a promising therapy for cancer treatment. This therapy also has...
Fig. 7 CAR exosomes do not cause cytokine release syndrome in mice. a Killing activity of CAR-T-T1E cells in response to tumour cells. The cytotoxic activity of CAR-T-T1E and control T cells against cancer cell lines was assessed by the 51Cr-release assay at the indicated effector-to-target (E:T) ratios. b Tumour volumes of MDA-MB-231 tumour xenografts after the indicated treatment, n = 8. c ELISA (left) of CAR on exosomes from CAR-T-T1E and transmission electron micrographs of CAR-EXO-T1E (right). Scale bars = 100 nm. d Cytotoxic activity of CAR exosomes and control T cells against cancer cell lines was assessed by the 51Cr-release assay at the indicated concentration. e Tumour volumes of MDA-MB-231 tumour xenografts after the indicated treatment, n = 8. Arrows indicate the treatment point (e). f Three groups of three tumour-free mice were treated i.p. with CAR-T-T1E cells at the indicated escalating doses. Serial weight measurements were performed and normalized to the starting body weight for each animal. The Kaplan-Meier survival curve of mice in all three groups is shown on the right. g Serum levels of human (h) and mouse (m) cytokines, measured at the indicated time points. h Three groups of three tumour-free mice were treated i.p. with CAR-EXO-T1E cells at the indicated escalating doses. Serial weight measurements were performed and normalized to the starting body weight for each animal. The Kaplan-Meier survival curve of mice in all three groups is shown on the right. i Serum levels of human (h) and mouse (m) cytokines, measured at the indicated time points. Arrows (b, e) indicate the treatment point. Results shown represent the (c) independent experiments. The data are presented as the means ± s.d. of six (a); four (c) or three (f-i) independent biological replicates or means ± s.e.m. three (f-i) independent biological replicates. P values are from a nonparametric t test (a, b, d, e) or a two-sided unpaired t test (c). Source data (a-i) are provided as a Source Data file.

some limitations or defects in the context of the volatility and complexity of cancer. Our data showed that CAR exosomes can act as eventual attackers, thereby conquering some of the limitations of the current treatment models. Applying appropriately both cellular and exosomal platforms, CAR-based treatment will be more effective and might be the next promising option for targeted cancer treatment.

Methods

Cell lines, antibodies and recombinant proteins. All cell lines were purchased from the American Type Culture Collection (ATCC, Manassas, VA). The identities of the cell lines were verified by STR analysis, and the cell lines were confirmed to be mycoplasma free. The cells were maintained in DMEM with 10% foetal bovine serum. Cell culture media and supplements were obtained from Life Technologies, Inc. Recombinant human PD-1L1/B7-H1 Fc chimera protein was obtained from R&D Systems (Minneapolis, MN). Cetuximab was purchased from Merck. Trastuzumab and atezolizumab were purchased from Roche Ltd. Residues 1–619 of the extracellular domain of EGFR (EGFR-ECD) and residues 1–646 of HER2-ECD were prepared using the pCDNA3.4 expression vector (Invitrogen) and Freestyle 293 expression system (Invitrogen) [14,35]. Information about the primary antibodies used in this work is included in Supplementary Table 2.

Vector construction. The sequence encoding the scFv antibodies generated from cetuximab or trastuzumab was chemically synthesized. As the targeting of HER2 with high affinity CAR-T cells was reported to lead to serious toxicity due to targeted recognition on normal cardiopulmonary tissue [26], the 4DS-5 scFv derived from trastuzumab was chosen for this study, which exhibited robust antitumour efficacy against HER2-overexpressing cancer cells both in vitro and in xenogeneic mouse tumour models but spared normal cells expressing physiologic target levels [27,58]. As shown in Fig. 1a, CAR-CTX and CAR-TTZ contained the human CD8α transmembrane region of the human CD8 molecule, and intracellular signalling domains of the CD137 and CD3ζ molecules. Similar construction methods were further used for CAR-T1E [42]. The fragments were subcloned into the pELNS vector [29]. High-titre replication-defective lentiviral vectors were produced and concentrated [30].

In vitro T cell transduction and cultures. Negative selection using RosetteSep kits (Stem Cell Technologies) was adopted to isolate primary human T cells from healthy volunteer donors following leukapheresis. All specimens were collected under an approved protocol by the Second Military Medical University Review Board, and written informed consent was obtained from each donor. Dynabeads Human T-Activator CD3/CD28 (Life Technologies) used to stimulate T cells were cultured in RPMI 1640 medium supplemented with 10% foetal calf serum, HEPES buffer (20 mM), and concentrated 59. High-titre replication-defective lentiviral vectors were produced and concentrated [30].
functional assays or are used for restimulation and purification of exosomes. T cells from the first stimulation were normalized to 30% CAR+ and were cocultured with either antigen-presenting cancer cells or Dynabeads Human T-Activator CD3/CD28 at a 1:1 ratio (second stimulation). Antigen-expressing cancer cells were irradiated with 100 Gy of γ-irradiation and washed before co-culture. In the second stimulation period, IL-2 (120 IU/ml) was added every other day.

**Cytotoxicity assays.** Cytotoxicity of the CAR-expressing T cells or exosomes was tested in a standard 4-h 3Cr-release assay. Target cells were labelled with 51Cr for 1 h. After centrifugation at 800 ×g for 10 min, 1 × 105 target cells were incubated for 2 h at 4 °C. Free binding sites were blocked with 200 μl of blocking buffer for 1 h at room temperature. For the detection of IFN-γ production, CAR-T cells were harvested and measured according to the manufacturer’s protocol. Supernatants of target cells were collected and washed twice with PBS on a magnetic rack to eliminate unbound or detached cells. The supernatants were then mixed with 10% non-fat dry milk at room temperature for 1 h before adding a fixed amount of labelled target cells (n = 5000) at a 1:1000 target to effector ratio. Effector cells were added at a volume of 100 μl at different E/T ratios. Exosomes were tested at different concentrations. CAR-T cells or exosomes and targets were incubated together for 4 h at 37 °C. The supernatant (30 μl) from each well was transferred to the plates, which were washed to remove unbound or undetached CAR-expressing T cells or exosomes. Supernatants were treated with 0.1 M sodium citrate/citric acid and were immediately equilibrated to the desired pH.

**ELISA.** To detect CAR expression on EVs or cell supernatants, ELISA plates (96-well) (Biolegend) were coated with 0.25 μg per well (100 μl) of recombinant antigen (EGFR or HER2) overnight at 4 °C. Free binding sites were blocked with 200 μl of blocking buffer (Pierce) for 1 h at room temperature. Next,extracellular vesicle samples purified from cell culture supernatants were added to each well. The exosomes or microvesicle samples purified from culture cell supernatants were prepared by serial dilution according to the total protein level to analyse the expression of CAR on exosomes and microvesicles. The concentration of CAR on the surface of exosomes isolated from the indicated cells was calculated based on the linear range of the ELISA data. After overnight incubation at 4 °C, MYC Tag Monoclonal Antibody (R950-25, Invitrogen) was added to each well and incubated for 1 h at room temperature. A total of 100 μl per well of horseradish peroxidase-conjugated secondary antibody (BD Biosciences) diluted in PBS containing 0.1% BSA was added and incubated for 1 h at room temperature. The plates were developed with tetramethylbenzidine (Pierce), and the reactions were stopped with 50 μl of 30% H2SO4. The plates were read at 450 nm using a BioTek plate reader. Recombinant MYC-tagged scFv protein was used to make a standard curve. Recombinant P-selectin protein (R&D Systems; Cat# 137-PS) was used as a negative control to verify the detection specificity. The results of the standard curve demonstrated that the established ELISA exhibited a reliable linear detection range from 0.2 to 25 ng/ml. For the detection of IFN-γ, TNF and IL-2, the supernatant of CAR-T cells was harvested and measured according to the manufacturer’s instructions (Biolegend).

**Exosomal binding assay.** To test the binding of exosomal CAR to antigen, 100 μl of exosome samples of different concentrations was captured onto recombinant antigen immobilized on 96-well plates overnight at 4 °C. Supernatants of labelled target cells (n = 5000) were placed in each well of a 96-well plate. Effector cells were added at a volume of 100 μl at different E/T ratios. Supernatants were tested at different concentrations. CAR-T cells or exosomes and targets were incubated together for 4 h at 37 °C. The supernatant (30 μl) from each well was transferred to the plates, which were washed to eliminate unbound or undetached CAR-expressing T cells or exosomes. Supernatants were treated with 0.1 M sodium citrate/citric acid and were immediately equilibrated to the desired pH.

**Flow cytometry.** Purified exosomes were incubated with 4-μm-diameter aldehyde/sulphate latex beads (Interfacial Dynamics) in PBS overnight at 4 °C under gentle agitation. Exosomes or cell surface staining was performed for 30 min at 4 °C, and analysed using a FACS caliber flow cytometer (BD Biosciences) and CellQuest Software (BD Biosciences). Intra-exosome or cellular staining was performed for 60 min on ice after using a fixation/permeabilization kit (eBioscience). A minimum of 1 x 10^6 beads/sample was examined.

**Immunofluorescence staining.** To verify the physical interactions between exosomes and cancer cells, purified exosomes were stained with NHS-Rhodamine (Pierce) in 100 μl PBS, washed with 10 μl PBS and pelleted by ultracentrifugation. MCF7-EGFR or MCF-HER2 cells were treated with Rho-labelled exosomes (25 μg/ml) for 2 h and then fixed for confocal microscopy after immunostaining for cancer cells. For immunofluorescence staining, the cells were plated on cover slides, fixed with 4% paraformaldehyde, permeabilized with 0.3% Triton X-100, and blocked with 1% BSA. The primary antibodies were incubated overnight and subjected to the corresponding fluorescent dye-conjugated secondary antibody for labelling. Nuclei were stained with DAPI. The samples were observed, and pictures were taken using a Leica TCS SP2 confocal system (Leica, Germany).

**Western blot analysis.** Whole-cell lysates or exosomal proteins were separated using SDS-PAGE and transferred onto PVDF membranes. The blots were blocked with 10% non-fat dry milk at room temperature for 1 h and were incubated overnight at 4 °C with the corresponding primary antibodies at dilutions recommended by the suppliers, followed by incubation with HRP-conjugated secondary antibodies (Cell Signalling Technology) at room temperature for 1 h. The blots on the membranes were developed using ECL detection reagents (Pierce). CD63, Hrs, Alix, and TSG101 were used as exosome markers. GAPDH was used as a loading control.

**Repeat-dose toxicity studies.** A 13-week repeat-dose toxicity study with a 4-week recovery period was conducted to evaluate the safety of all drugs used in the in vivo experiments. The groups of SCID mice were dosed with 2 x 10^7, 1 x 10^8, or 1 x 10^9 CAR-T cells or 25, 50, 100 or 150 μg of exosomes once weekly. Mice were monitored for visible signs of toxicity and body weight loss. The MTD was defined as the dose at which no deaths occurred and the body weight loss was ≤20% of the pretreatment animal weight. Upon termination of the study, the animals were sacrificed, and tissue from the selected mice was harvested and subjected to histopathologic analysis.

**Quantitative PCR (qPCR).** Total RNA was isolated using the RNeasy Mini Kit (Qiagen), according to the manufacturer’s specifications. Real-time quantitative PCR was performed on an ABI PRISM 7900HT and analysed using the SDS v2.3 (Applied Biosystems). GAPDH was used as an internal control. Information about the primers is included in Supplementary Table 3.

**In vivo study.** In vivo experiments were approved by the Institutional Animal Care and Use Committee (IACUC) of Second Military Medical University, and mice were housed in a specific pathogen-free barrier facility. Cancer cells were inoculated into BALB/c nude mice (Shanghai Experimental Animal Centre of Chinese Academy of Sciences). When the tumour volumes reached an average of approximately 100 mm^3, the mice were randomly divided into groups of 6—10 mice each. The mice were injected i.p. with 200 μg/kg cyclophosphamide to deplete the host lymphocyte compartments. For patient-derived xenograft models, patient specimens were obtained during initial surgery from primary-diagnosed, early-stage cancer patients at Changzhai Hospital of Second Military Medical University. The xenografts were treated and stained with the local ethics committee of Changzhai Hospital, Second Military Medical University approved experimental design and tissue samples collection. Tumour pathology results were consistent with previous reports. The results were consistent with previous reports.
was evaluated by hospital pathologists. Minimally passaged human tumour xenograft models and tumour-initiating cell frequency were established in mice.

Briefly, human tumour xenograft models were established by subcutaneous implantation of patient-derived solid tissue fragments in NOD/SCID mice (Animal Centre of Chinese Academy of Sciences). All animals were treated in accordance with the guidelines of the Committee on Animals of the Second Military Medical University. The growing tumours were allowed to engraft to approximately 100 mm³ prior to treatment. Multiple-dose studies consisted of weekly treatment. The tumours were measured with digital callipers, and the tumour volumes were calculated by the following formula: volume = length x (width)²/2. For cell treatment, CAR-T cells or exosomes were i.v. or i.t. injected into mice every week for the entire course of the treatment with the indicated dose. Mice were i.p. injected with 2000 units of IL-2 twice a week following infusion. Mice were killed 40 days after treatment or if the volume of the tumours reached 1300 mm³ cm² before 35 days.

Recombinant PD-L1 or PD-L1 Ab was used when necessary at a dose of 10 mg/kg very week. The percentage TGI compared with controls was calculated at the end of the study when indicated.

Statistical analysis. Unless otherwise specified, Student’s t test was used to calculate the significance of differences between two groups, and ANOVA was used to evaluate differences among three or more groups. Differences between samples were considered statistically significant when P < 0.05.

Reporting Summary. Further information on research design is available in the Nature Research Reporting Summary linked to this article.

Data availability

The authors declare that the data supporting the findings of this study are available within the paper and its Supplementary Information files or from the corresponding author on reasonable request. The source data underlying Figs. 1c, 2b–d, 3d, 4b, c, 5a–d, 6a–f and 7a–i and Supplementary Figs. 2a–c, 3a–c, 4a, b, 5, 6 and 8a–c are provided as a Source Data file.

Received: 26 March 2018 Accepted: 3 September 2019

References

1. Rosenberg, S. A. & Restifo, N. P. Adoptive cell transfer as personalized immunotherapy for human cancer. Science 348, 62–68 (2015).
2. June, C. H., Biddell, S. R. & Schumacher, T. N. Adoptive cellular therapy: a race to the finish line. Sci. Transl. Med. 7, 280ps287–280ps287 (2015).
3. Porter, D. L., Levine, B. L., Kalos, M., Bagg, A. & June, C. H. Chimeric antigen receptor-modified T cells in chronic lymphoid leukemia. N. Engl. J. Med. 365, 725–733 (2011).
4. Neelapu, S. S. et al. Chimeric antigen receptor T-cell therapy—assessment and management of toxicities. Nat. Rev. Clin. Oncol. 15, 47 (2018).
5. Lee, D. W. et al. Molecules relevant for T cell-target cell interaction are present in cytolytic granules of human T lymphocytes. Eur. J. Immunol. 19, 1469–1475 (1989).
6. Lee, D. W. et al. Current concepts in the diagnosis and management of cytokine release syndrome. J. Clin. Invest. 111, 28–32 (1990).
7. Peters, P. et al. J. Interferon Cytokine Res. 24, 1021–1030 (2004).
8. Neelapu, S. S. et al. Kte-C19 (anti-CD19 CAR T Cells) Induces Complete Remissions in Patients with Refractory Diffuse Large B-Cell Lymphoma (DLBCL): Results from the Pivotal Phase 2 Zuma-1. Blood 129, 341–345 (2017).
9. Levine, B. L. et al. Gene transfer in humans using a conditionally replicating lentiviral vector. Proc. Natl Acad. Sci. USA 103, 17372–17377 (2006).
10. Peters, P. J. et al. Molecules relevant for T cell-target cell interaction are present in cytolytic granules of human T lymphocytes. Eur. J. Immunol. 19, 1469–1475 (1989).
11. Peters, P. J. et al. Cytotoxic T lymphocyte granules are secretory lysosomes, containing both perforin and granzymes. J. Exp. Med. 169, 1099–1109 (1989).
12. Peters, P. J., Geuze, H. J., van der Donk, H. A. & Borst, J. A new model for lethal hit delivery by cytokine-induced T lymphocytes. Immunol. Today 11, 28–32 (1990).
13. Blanchard, N. et al. TCR activation of human T cells induces the production of exosomes bearing the TCR/CD3/CD2 complex. J. Immunol. 168, 3235–3241 (2002).
14. Raposo, G. & Stoorvogel, W. Extracellular vesicles: exosomes, microvesicles, and friends. J. Cell Biol. 200, 373–383 (2013).
15. Colombo, M., Raposo, G. & Théry, C. Biogenesis, secretion, and intercellular interactions of exosomes and other extracellular vesicles. Annu. Rev. Cell Dev. Biol. 30, 255–289 (2014).
16. Alhasan, A. H., Patel, P. C., Choi, C. H. J. & Mirkin, C. A. Exosome enclosed spherical nucleic acid gold nanoparticle conjugates as potent microRNA regulation agents. Small 10, 186–192 (2014).
17. Alvarez-Erviti, L. et al. Delivery of siRNA to the mouse brain by systemic injection of targeted exosomes. Nat. Biotechnol. 29, 341–345 (2011).
18. Levine, B. L. et al. Effects of CD28 costimulation on long-term proliferation of CD4+ T cells in the absence of exogenous feeders. Cell 159, 5921–5930 (1997).
19. Théry, C., Amigorena, S., Raposo, G. & Clayton, A. Isolation and characterization of exosomes from cell culture supernatants and biological fluids. Curr. Protoc. Cell Biol. 3, Unit 5.2.2 (2006).
20. Jackson, H. J., Raftig, S. & Brentjens, R. J. Driving CAR-T cells forward. Nat. Rev. Clin. Oncol. 13, 370 (2016).
21. Calluri, R. The biology and function of exosomes in cancer. J. Clin. Invest. 126, 1208 (2016).
22. Colombo, M., Raposo, G. & Théry, C. Biogenesis, secretion, and intercellular interactions of exosomes and other extracellular vesicles. Annu. Rev. Cell Dev. Biol. 30, 255–289 (2014).
23. Schmidt, O. & Teis, D. The ESCRT machinery. Curr. Biol. 22, R116–R120 (2012).
24. Freeman, G. J. et al. Engagement of the PD-1 immunoinhibitory receptor by a novel B7 family member leads to negative regulation of lymphocyte activation. J. Exp. Med. 192, 1027–1034 (2000).
25. Latchman, Y. et al. PD-L2 is a second ligand for PD-1 and inhibits T cell activation. Nat. Immunol. 2, 261–268 (2001).
26. Ozkaynak, E. et al. Programmed death-1 targeting can promote allograft survival. J. Immunol. 169, 6546–6553 (2002).
27. Gao, W., Demirci, G., Strom, T. B. & Li, X. Stimulating PD-1-negative signals concurrent with blocking CD154 co-stimulation induces long-term allograft survival. Blood 121, 3588–3596 (2008).
28. Song, M. Y. et al. Protective effects of Fc-fused PD-L1 on two different animal models of colitis. Gut 64, 260–271 (2015).
29. Davies, D. M. et al. Flexible targeting of ErbB dimers that drive tumorigenesis by using genetically engineered T cells. Mol. Med. 18, 565 (2012).
30. van der Stegen, S. J. et al. Preclinical in vivo modeling of cytokine release syndrome induced by ErbB-targeted human T cells identifying a window of therapeutic opportunity? J. Immunol. 191, 4589–4598 (2013).
31. Pule, M. A. et al. Virus-specific T cells engineered to coexpress tumor-specific receptors: persistence and antitumor activity in individuals with neuroblastoma. Nat. Med. 14, 1264–1270 (2008).
32. Pule, M. A. et al. High-dose chemotherapy and adoptive immunotherapy in the treatment of recurrent pediatric brain tumors. Neuropediatrics 39, 151–156 (2008).
46. Gilham, D. E., Debets, R., Pule, M., Hawkins, R. E. & Abken, H. CAR-T cells and solid tumors: tuning T cells to challenge an inveterate foe. Trends Mol. Med. 18, 377–384 (2012).
47. Gajewski, T. F. et al. Cancer immunotherapy strategies based on overcoming barriers within the tumor microenvironment. Curr. Opin. Immunol. 25, 268–276 (2013).
48. Fearon, D. T. The carcinoma-associated fibroblast expressing fibroblast activation protein and escape from immune surveillance. Cancer Immunol. Res. 2, 187–193 (2014).
49. Ruella, M. et al. Induction of resistance to chimeric antigen receptor T cell therapy by transduction of a single leukemic B cell. Nat. Med. 24, 1499 (2018).
50. Awada, S. E., Lakhal, S., Mäger, I. & Wood, M. J. Exosomes for targeted siRNA delivery across biological barriers. Adv. Drug Deliv. Rev. 65, 391–397 (2013).
51. Cheruvanya, A. et al. Rapid isolation of urinary exosomal biomarkers using a nanomembrane ultrafiltration concentrator. Am. J. Physiol. Renal Physiol. 292, F1657–F1661 (2007).
52. Lassar, C. Eldh, M. & Lotvall, J. Isolation and characterization of RNA-containing exosomes. J. Vis. Exp. 59, e3037 (2012).
53. Sverdlov, E. D. Amedeo Avogadro’s cry: what is 1 µg of exosomes? Bioessays 34, 873–875 (2012).
54. Hu, S. et al. Antagonism of EGFR and Notch limits resistance to EGFR inhibitors and radiation by decreasing tumor-initiating cell frequency. Sci. Transl. Med. 9, eaag0339 (2017).
55. Hu, S. et al. Four-in-one antibodies have superior cancer inhibitory activity against EGFR, HER2, HER3, and VEGF through disruption of HER/MET crosstalk. Cancer Res. 75, 159–170 (2015).
56. Morgan, R. A. et al. Case report of a serious adverse event following the administration of T cells transduced with a chimeric antigen receptor recognizing ERBB2. Mol. Ther. 18, 843–851 (2010).
57. Liu, X. et al. Affinity-tuned ErbB2 or EGFR chimeric antigen receptor T cells exhibit an increased therapeutic index against tumors in mice. Cancer Res. 75, 3596–3607 (2015).
58. Roybal, K. T. et al. Engineering T cells with customized therapeutic response programs using synthetic notch receptors. Cell 167, 419–432. e416 (2016).
59. Carpenito, C. et al. Control of large, established tumor xenografts with genetically retargeted human T cells containing CD28 and CD137 domains. Proc. Natl. Acad. Sci. USA 106, 3360–3365 (2009).
60. Hao, S., Yuan, J. & Xiang, J. Nonspecific CD4+ T cells with uptake of antigen-specific dendritic cell-released exosomes stimulate antigen-specific CD8+ CTL responses and long-term T cell memory. J. Leukoc. Biol. 82, 829–838 (2007).
61. Robbins, P. D. & Morell, A. E. Regulation of immune responses by extracellular vesicles. Nat. Rev. Immunol. 14, 195–208 (2014).
62. Peinado, H. et al. Melanoma exosomes educate bone marrow progenitor cells toward a pro-metastatic phenotype through MET. Nat. Med. 18, 883–891 (2012).
63. Chen, G. et al. Exosomal PD-L1 contributes to immunosuppression and is associated with anti-PD-1 response. Nature 560, 382–386 (2018).
64. Dalerba, P. et al. Phenotypic characterization of human colorectal cancer stem cells. Proc. Natl. Acad. Sci. USA 104, 10158–10163 (2007).